Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Authors:
Top Cited Papers
Open Access
- 16 July 2014
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 512 (7512) , 49-53
Abstract
In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the teratogenicity of thalidomide and its derivatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-deletion-associated dysplasia. IMiDs target the E3 ubiquitin ligase CUL4–RBX1–DDB1–CRBN (known as CRL4CRBN) and promote the ubiquitination of the IKAROS family transcription factors IKZF1 and IKZF3 by CRL4CRBN. Here we present crystal structures of the DDB1–CRBN complex bound to thalidomide, lenalidomide and pomalidomide. The structure establishes that CRBN is a substrate receptor within CRL4CRBN and enantioselectively binds IMiDs. Using an unbiased screen, we identified the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4CRBN. Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4CRBN while the ligase complex is recruiting IKZF1 or IKZF3 for degradation. This dual activity implies that small molecules can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.Keywords
This publication has 42 references indexed in Scilit:
- Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapyOncogene, 2013
- The application and biology of immunomodulatory drugs (IMiDs) in cancerPharmacology & Therapeutics, 2012
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010
- The thalidomide sagaThe International Journal of Biochemistry & Cell Biology, 2007
- The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer, 2004
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide in the treatment of lepra reactionsClinical Pharmacology & Therapeutics, 1965
- THALIDOMIDE AND CONGENITAL ABNORMALITIESThe Lancet, 1962
- THALIDOMIDE AND CONGENITAL ABNORMALITIESThe Lancet, 1961